Home > Research > Publications & Outputs > Symptom control and survival for people severel...

Links

Text available via DOI:

View graph of relations

Symptom control and survival for people severely ill with COVID: a multicentre cohort study (CovPall-Symptom)

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Symptom control and survival for people severely ill with COVID: a multicentre cohort study (CovPall-Symptom). / Higginson, Irene; Hocaoglu, Mevhibe; Fraser, Lorna et al.
In: Journal of Pain and Symptom Management, Vol. 64, No. 4, 31.10.2022, p. 377-390.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Higginson, I, Hocaoglu, M, Fraser, L, Maddocks, M, Sleeman, K, Oluyase, A, Chambers, R, Preston, N, Dunleavy, L, Bradshaw, A, Bajwah, S, Murtagh, F & Walshe, C 2022, 'Symptom control and survival for people severely ill with COVID: a multicentre cohort study (CovPall-Symptom)', Journal of Pain and Symptom Management, vol. 64, no. 4, pp. 377-390. https://doi.org/10.1016/j.jpainsymman.2022.06.009

APA

Higginson, I., Hocaoglu, M., Fraser, L., Maddocks, M., Sleeman, K., Oluyase, A., Chambers, R., Preston, N., Dunleavy, L., Bradshaw, A., Bajwah, S., Murtagh, F., & Walshe, C. (2022). Symptom control and survival for people severely ill with COVID: a multicentre cohort study (CovPall-Symptom). Journal of Pain and Symptom Management, 64(4), 377-390. https://doi.org/10.1016/j.jpainsymman.2022.06.009

Vancouver

Higginson I, Hocaoglu M, Fraser L, Maddocks M, Sleeman K, Oluyase A et al. Symptom control and survival for people severely ill with COVID: a multicentre cohort study (CovPall-Symptom). Journal of Pain and Symptom Management. 2022 Oct 31;64(4):377-390. Epub 2022 Jun 23. doi: 10.1016/j.jpainsymman.2022.06.009

Author

Higginson, Irene ; Hocaoglu, Mevhibe ; Fraser, Lorna et al. / Symptom control and survival for people severely ill with COVID : a multicentre cohort study (CovPall-Symptom). In: Journal of Pain and Symptom Management. 2022 ; Vol. 64, No. 4. pp. 377-390.

Bibtex

@article{6b3ec952c8ac4abf8a16c3e52e3e4b83,
title = "Symptom control and survival for people severely ill with COVID: a multicentre cohort study (CovPall-Symptom)",
abstract = "Context: Evidence of symptom control outcomes in severe COVID is scant. Objectives: To determine changes in symptoms among people severely ill or dying with COVID supported by palliative care, and associations with treatments and survival. Methods: Multicentre cohort study of people with COVID across England and Wales supported by palliative care services, during the pandemic in 2020 and 2021. We analysed clinical, demographic and survival data, symptom severity at baseline (referral to palliative care, first COVID assessment) and at three follow-up assessments using the Integrated Palliative care Outcome Scale – COVID version. Results: We included 572 patients from 25 services, mostly hospital support teams; 496 (87%) were newly referred to palliative care with COVID, 75 (13%) were already supported by palliative care when they contracted COVID. At baseline, patients had a mean of 2.4 co-morbidities, mean age 77 years, a mean of five symptoms, and were often bedfast or semiconscious. The most prevalent symptoms were: breathlessness, weakness/lack of energy, drowsiness, anxiety, agitation, confusion/delirium, and pain. Median time in palliative care was 46 hours; 77% of patients died. During palliative care, breathlessness, agitation, anxiety, delirium, cough, fever, pain, sore/dry mouth and nausea improved; drowsiness became worse. Common treatments were low dose morphine and midazolam. Having moderate to severe breathlessness, agitation and multimorbidity were associated with shorter survival. Conclusion: Symptoms of COVID quickly improved during palliative care. Breathlessness, agitation and multimorbidity could be used as triggers for timelier referral, and symptom guidance for wider specialities should build on treatments identified in this study.",
keywords = "Symptom Treatment, Symptom Management, COVID, Palliative care, Integrated Palliative Outcome Scale, Specialist Palliative Care, Acute Hospital Ward, Hospice",
author = "Irene Higginson and Mevhibe Hocaoglu and Lorna Fraser and Matthew Maddocks and Katherine Sleeman and Adejoke Oluyase and Rachel Chambers and Nancy Preston and Lesley Dunleavy and Andy Bradshaw and Sabrina Bajwah and Fliss Murtagh and Catherine Walshe",
year = "2022",
month = oct,
day = "31",
doi = "10.1016/j.jpainsymman.2022.06.009",
language = "English",
volume = "64",
pages = "377--390",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Symptom control and survival for people severely ill with COVID

T2 - a multicentre cohort study (CovPall-Symptom)

AU - Higginson, Irene

AU - Hocaoglu, Mevhibe

AU - Fraser, Lorna

AU - Maddocks, Matthew

AU - Sleeman, Katherine

AU - Oluyase, Adejoke

AU - Chambers, Rachel

AU - Preston, Nancy

AU - Dunleavy, Lesley

AU - Bradshaw, Andy

AU - Bajwah, Sabrina

AU - Murtagh, Fliss

AU - Walshe, Catherine

PY - 2022/10/31

Y1 - 2022/10/31

N2 - Context: Evidence of symptom control outcomes in severe COVID is scant. Objectives: To determine changes in symptoms among people severely ill or dying with COVID supported by palliative care, and associations with treatments and survival. Methods: Multicentre cohort study of people with COVID across England and Wales supported by palliative care services, during the pandemic in 2020 and 2021. We analysed clinical, demographic and survival data, symptom severity at baseline (referral to palliative care, first COVID assessment) and at three follow-up assessments using the Integrated Palliative care Outcome Scale – COVID version. Results: We included 572 patients from 25 services, mostly hospital support teams; 496 (87%) were newly referred to palliative care with COVID, 75 (13%) were already supported by palliative care when they contracted COVID. At baseline, patients had a mean of 2.4 co-morbidities, mean age 77 years, a mean of five symptoms, and were often bedfast or semiconscious. The most prevalent symptoms were: breathlessness, weakness/lack of energy, drowsiness, anxiety, agitation, confusion/delirium, and pain. Median time in palliative care was 46 hours; 77% of patients died. During palliative care, breathlessness, agitation, anxiety, delirium, cough, fever, pain, sore/dry mouth and nausea improved; drowsiness became worse. Common treatments were low dose morphine and midazolam. Having moderate to severe breathlessness, agitation and multimorbidity were associated with shorter survival. Conclusion: Symptoms of COVID quickly improved during palliative care. Breathlessness, agitation and multimorbidity could be used as triggers for timelier referral, and symptom guidance for wider specialities should build on treatments identified in this study.

AB - Context: Evidence of symptom control outcomes in severe COVID is scant. Objectives: To determine changes in symptoms among people severely ill or dying with COVID supported by palliative care, and associations with treatments and survival. Methods: Multicentre cohort study of people with COVID across England and Wales supported by palliative care services, during the pandemic in 2020 and 2021. We analysed clinical, demographic and survival data, symptom severity at baseline (referral to palliative care, first COVID assessment) and at three follow-up assessments using the Integrated Palliative care Outcome Scale – COVID version. Results: We included 572 patients from 25 services, mostly hospital support teams; 496 (87%) were newly referred to palliative care with COVID, 75 (13%) were already supported by palliative care when they contracted COVID. At baseline, patients had a mean of 2.4 co-morbidities, mean age 77 years, a mean of five symptoms, and were often bedfast or semiconscious. The most prevalent symptoms were: breathlessness, weakness/lack of energy, drowsiness, anxiety, agitation, confusion/delirium, and pain. Median time in palliative care was 46 hours; 77% of patients died. During palliative care, breathlessness, agitation, anxiety, delirium, cough, fever, pain, sore/dry mouth and nausea improved; drowsiness became worse. Common treatments were low dose morphine and midazolam. Having moderate to severe breathlessness, agitation and multimorbidity were associated with shorter survival. Conclusion: Symptoms of COVID quickly improved during palliative care. Breathlessness, agitation and multimorbidity could be used as triggers for timelier referral, and symptom guidance for wider specialities should build on treatments identified in this study.

KW - Symptom Treatment

KW - Symptom Management

KW - COVID

KW - Palliative care

KW - Integrated Palliative Outcome Scale

KW - Specialist Palliative Care

KW - Acute Hospital Ward

KW - Hospice

U2 - 10.1016/j.jpainsymman.2022.06.009

DO - 10.1016/j.jpainsymman.2022.06.009

M3 - Journal article

VL - 64

SP - 377

EP - 390

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 4

ER -